financetom
Business
financetom
/
Business
/
AT&T Maintains Full-Year Outlook as Quarterly Postpaid Subscriber Growth Tops Estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AT&T Maintains Full-Year Outlook as Quarterly Postpaid Subscriber Growth Tops Estimates
Jul 24, 2024 6:46 AM

09:28 AM EDT, 07/24/2024 (MT Newswires) -- AT&T's ( T ) second-quarter earnings fell year over year while the telecommunication giant added more postpaid phone subscribers than expected and maintained its full-year earnings outlook.

The company's adjusted earnings came in at $0.57 per share for the June quarter, in line with the Capital IQ-polled consensus, but down from $0.63 a year earlier. Revenue edged down 0.4% to $29.8 billion, falling short of the Street's view for $29.98 billion.

"Our solid performance this quarter demonstrates the durable benefits of our investment-led strategy," Chief Executive John Stankey said in a statement. Shares of AT&T ( T ) were up 3.6% in recent premarket activity.

Communications revenue decreased 0.9% year over year to $28.58 billion. Within mobility, service revenue rose 3.4% to $16.28 billion, while equipment revenue dropped 8% to $4.2 billion due to lower volumes. Consumer wireline rose 3% to $3.35 billion, boosted by broadband gains. Business wireline revenue fell 9.9% to $4.76 billion amid reduced demand for legacy voice and data services.

AT&T ( T ) added 419,000 net postpaid phone subscribers in the quarter, up from 326,000 last year and 349,000 in the prior three-month period. The consensus on Visible Alpha was for a 266,100 net increase.

Total operating expenses rose to $24.04 billion from $23.51 billion in the prior-year quarter. The increase was due to higher depreciation related to the company's continued investment in fiber and 5G technology, accelerated depreciation on wireless network equipment and restructuring charges.

AT&T ( T ) continues to project adjusted EPS in a range of $2.15 to $2.25 for 2024, while the Street is looking for $2.21. The company said it reiterated its revenue growth outlook in "the 3% range" for wireless service and more than 7% for broadband.

Price: 18.69, Change: +0.48, Percent Change: +2.64

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
QXO Agrees to $3.5 Billion in Financing Through Private Placement
QXO Agrees to $3.5 Billion in Financing Through Private Placement
Jun 14, 2024
04:53 AM EDT, 06/14/2024 (MT Newswires) -- QXO (QXO) said late Thursday it has agreed to $3.5 billion in financing via a private placement of shares and warrants with institutional and accredited investors. Under the terms of the deal, the company is selling around 340.9 million common shares for $9.14 per share, and 42 million pre-funded warrants for $9.13999 per...
Zapp Electric Vehicles Signs Distribution Contract in India
Zapp Electric Vehicles Signs Distribution Contract in India
Jun 14, 2024
05:00 AM EDT, 06/14/2024 (MT Newswires) -- Zapp Electric Vehicles Group ( ZAPP ) said it intends to appoint Bounce Electric 1 Private Limited as its contract manufacturing partner for the sales of the i300 in India. The British electric vehicle brand signed a memorandum of understanding to this effect. It said on Thursday Bounce operates a domestic vehicle assembly...
Riot Platforms Discloses 14% Stake in Bitfarms, Seeks Special Meeting to Revamp Board
Riot Platforms Discloses 14% Stake in Bitfarms, Seeks Special Meeting to Revamp Board
Jun 14, 2024
04:56 AM EDT, 06/14/2024 (MT Newswires) -- Riot Platforms ( RIOT ) said late Thursday it had added about 1.4 million shares to its investment in Bitfarms ( BITF ) , bringing its total stake to 14% of the shares of the rival cryptocurrency miner, and intends to call for a special meeting to nominate new members to Bitfarm's board....
Cabaletta Bio Says Autoimmune Disease Therapy Showed Promise in Early Results
Cabaletta Bio Says Autoimmune Disease Therapy Showed Promise in Early Results
Jun 14, 2024
05:02 AM EDT, 06/14/2024 (MT Newswires) -- Cabaletta Bio ( CABA ) said Friday initial data from each of the first two patients dosed with its CABA-201 experimental therapy to treat autoimmune disease in early-to-mid-stage studies showed the treatment was well-tolerated and potentially effective in resetting the immune system. The company said the data showed no serious adverse events, cytokine...
Copyright 2023-2026 - www.financetom.com All Rights Reserved